Sarepta Therapeutics to Announce Third Quarter 2016 Financial Results and Recent Corporate Developments on October 27, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage developer of innovative RNA-targeted therapeutics, will report third quarter 2016 financial results before the NASDAQ Global Market opens on Thursday, October 27, 2016. Subsequently, at 8:00 a.m., Eastern Time, Edward Kaye, M.D., Sarepta’s chief executive officer, Sandy Mahatme, Sarepta’s chief financial officer, and Bo Cumbo, Sarepta’s senior vice president of global commercial development will host a conference call to discuss third quarter financial results and to provide a corporate update.

The conference call may be accessed by dialing (844) 534-7313 for domestic callers and (574) 990-1451 for international callers. The passcode for the call is 7029987. Please specify to the operator that you would like to join the "Sarepta Third Quarter 2016 Earnings Call." The conference call will be webcast live under the investor relations section of Sarepta's website at www.sarepta.com and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About SareptaSarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying DMD drug candidates. For more information, please visit us at www.sarepta.com.

Internet Posting of InformationWe routinely post information that may be important to investors in the 'For Investors' section of our web site at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161024005693/en/

Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
[email protected]
or
W2O Group
Brian Reid, 212-257-6725
[email protected]

Source: Sarepta Therapeutics, Inc.

You May Also Be Interested In

• Growth isn't weak enough to truly undercut inflation pressures - BMO
• Warren Buffet's Berkshire stock target raised at UBS into earnings
• Comerica (CMA) PT Raised to $54 at Piper Sandler